Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ketorolac × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4 Breast 3 Other 2 Lymphoid 2 Gastrointestinal 2 Thoracic 1 Plasma cell 1 Head & Neck 1 Gynecologic 1 Endocrine 1

Conditions

Multiple Endocrine Neoplasia Type 1 1 Emergencies 1

Interventions

Everolimus 53 lutetium Lu 177 dotatate 42 Magnetic Resonance Spectroscopy 27 Cisplatin 26 Temozolomide 25 pembrolizumab 24 Nivolumab 21 Octreotide 20 lanreotide 19 gallium Ga 68 dotatate 19 cabozantinib 18 Specimen Handling 17 Capecitabine 17 Etoposide 16 pasireotide 15 lenvatinib 15 Paclitaxel 15 dabrafenib 14 Sunitinib 14 Carboplatin 14 trametinib 13 Bevacizumab 13 3-Iodobenzylguanidine 12 surufatinib 11 Ipilimumab 11 Injections 11 Doxorubicin 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Thyrotropin Alfa 9 Sorafenib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01471639 2025-08-15

Sprix

The Cleveland Clinic

Phase NA Completed

37 enrolled 7 charts

Emergencies, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡